Last reviewed · How we verify
intraoperative aprotinin administration
intraoperative aprotinin administration is a Small molecule drug developed by Soroka University Medical Center. It is currently in Phase 1 development.
At a glance
| Generic name | intraoperative aprotinin administration |
|---|---|
| Sponsor | Soroka University Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- intraoperative aprotinin administration CI brief — competitive landscape report
- intraoperative aprotinin administration updates RSS · CI watch RSS
- Soroka University Medical Center portfolio CI
Frequently asked questions about intraoperative aprotinin administration
What is intraoperative aprotinin administration?
intraoperative aprotinin administration is a Small molecule drug developed by Soroka University Medical Center.
Who makes intraoperative aprotinin administration?
intraoperative aprotinin administration is developed by Soroka University Medical Center (see full Soroka University Medical Center pipeline at /company/soroka-university-medical-center).
What development phase is intraoperative aprotinin administration in?
intraoperative aprotinin administration is in Phase 1.